TW201919695A - 康納單抗(canakinumab)之用途 - Google Patents

康納單抗(canakinumab)之用途 Download PDF

Info

Publication number
TW201919695A
TW201919695A TW107129672A TW107129672A TW201919695A TW 201919695 A TW201919695 A TW 201919695A TW 107129672 A TW107129672 A TW 107129672A TW 107129672 A TW107129672 A TW 107129672A TW 201919695 A TW201919695 A TW 201919695A
Authority
TW
Taiwan
Prior art keywords
hscrp
patient
months
approximately
administration
Prior art date
Application number
TW107129672A
Other languages
English (en)
Chinese (zh)
Inventor
保羅 瑞德克
湯姆 索倫
喬琪娜 波曼
彼特 立比
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW201919695A publication Critical patent/TW201919695A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW107129672A 2017-08-25 2018-08-24 康納單抗(canakinumab)之用途 TW201919695A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762549971P 2017-08-25 2017-08-25
US62/549,971 2017-08-25
US201762584380P 2017-11-10 2017-11-10
US62/584,380 2017-11-10

Publications (1)

Publication Number Publication Date
TW201919695A true TW201919695A (zh) 2019-06-01

Family

ID=63643018

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107129672A TW201919695A (zh) 2017-08-25 2018-08-24 康納單抗(canakinumab)之用途
TW107129849A TW201919696A (zh) 2017-08-25 2018-08-27 康納單抗(canakinumab)之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107129849A TW201919696A (zh) 2017-08-25 2018-08-27 康納單抗(canakinumab)之用途

Country Status (5)

Country Link
US (3) US20200199220A1 (https=)
EP (2) EP3710475A1 (https=)
JP (2) JP2020531537A (https=)
TW (2) TW201919695A (https=)
WO (2) WO2019038737A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491820A (zh) * 2021-07-30 2021-10-12 复旦大学附属中山医院 涂层Canakinumab的药物球囊的制备及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021517141A (ja) * 2018-03-09 2021-07-15 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 心血管疾患のための組み合わせ治療
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
BR112014007253A2 (pt) 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491820A (zh) * 2021-07-30 2021-10-12 复旦大学附属中山医院 涂层Canakinumab的药物球囊的制备及应用

Also Published As

Publication number Publication date
US20200199220A1 (en) 2020-06-25
JP2020531539A (ja) 2020-11-05
JP2020531537A (ja) 2020-11-05
EP3710475A1 (en) 2020-09-23
EP3710476A1 (en) 2020-09-23
US20200239564A1 (en) 2020-07-30
WO2019038737A1 (en) 2019-02-28
US20240043525A1 (en) 2024-02-08
WO2019038740A1 (en) 2019-02-28
TW201919696A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
Calabrò et al. CRP and the risk of atherosclerotic events
US20240043525A1 (en) Use of canakinumab
De Luca et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study
de Jager et al. CCL3 (MIP-1α) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events
Park et al. Association of acroosteolysis with enhanced osteoclastogenesis and higher blood levels of vascular endothelial growth factor in systemic sclerosis
Santos-García et al. Impaired brachial flow-mediated dilation is a predictor of a new-onset vascular event after stroke
Ricart et al. Mean platelet volume does not seem to relate to thrombosis or posterior uveitis in Behçet's disease
De Groot et al. Risk factors and early detection of atherosclerosis in rheumatoid arthritis
KR20240096648A (ko) 죽상경화성 심혈관 질병을 포함하는, 아테롬성 동맥경화증을 위한 조합 요법
Cugno et al. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis
Ogawa et al. Increased levels of platelet-derived microparticles in pulmonary hypertension
Brie et al. Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets
Giordano et al. Rationale for early administration of PCSK9 inhibitors in acute coronary syndrome
Cimaglia et al. Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction
Zhang et al. Predictive value of the Naples prognostic score for cardiovascular outcomes in patients with chronic kidney disease receiving percutaneous coronary intervention
Wang et al. S100a9 lactylation triggers neutrophil trafficking and cardiac inflammation in myocardial ischemia/reperfusion injury
Fang et al. Lipoprotein (a) and high-risk coronary plaques: Mechanisms, characteristics, and emerging therapeutic strategies
Bjerre et al. Micro‐and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipients—An exploratory study
Sakagami et al. Clinical impact of beta-blockers at discharge on long-term clinical outcomes in patients with non-reduced ejection fraction after acute myocardial infarction
Dalman et al. Background and proposed design for a metformin abdominal aortic aneurysm suppression trial
Dominguez-Rodriguez et al. Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X
TW201929894A (zh) 對抗心臟疾病、心血管疾病及相關病況與症狀之治療及保護方法
Dotsenko et al. Candidate circulating biomarkers for the cardiovascular disease continuum
Undas et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin
Cole et al. Endothelin as a Treatment Target in Cardiovascular Diseases: A Recent Step Forward